This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

ACE inhibitors in chronic kidney disease (CKD)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • renin-angiotensin system blockade reduces proteinuria and retards chronic kidney disease progression independent of blood pressure lowering
    • nephroprotection reflects both hemodynamic and nonhemodynamic mechanisms that culminate in attenuation of proinflammatory and profibrotic mediators in the renal parenchyma
    • angiotensin-converting enzyme (ACE) inhibitors were originally shown to retard progression of type 1 diabetic nephropathy (1)
    • ACE inhibitors are more effective than other antihypertensives in slowing progression of nondiabetic kidney disease (2)
  • a review found that the effectiveness of ACE inhibitors is similar across various baseline risks for disease progression in non-diabetic nephropathy (3)
    • however when stratified according to degree of proteinuria
      • among the subgroup of patients with proteinuria > or =500 mg/d, significant treatment effect was seen across all patients with a measurable outcome risk, including those at relatively low risk (1.7% annualized risk for progression).
      • there was no benefit of ACEI therapy among patients with proteinuria <500 mg/d, even among higher risk patients (control outcome rate 19.7%)

Reference:


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.